We are thrilled to announce that he European Commission has authorised the extension of the Recomb RAG-1 SCID gene therapy trial by an additional 24 months, setting a new official end date for December 31, 2024. Thanks to this generous decision by the EU Horizon 2020 programme, this extension allows for continued advancements for this groundbreaking project. Read our press release below